iShares Nasdaq Biotechnology ETF (IBB)
310.52
+5.84 +1.92%
NASDAQ
Aug 22, 20:00
Delayed 2m
USD
IBB Key Stats
| Expense Ratio | 0.47% |
| Share Class Assets Under Management | 9.009B |
| 30-Day Average Daily Volume | Upgrade |
| Net Asset Value | 310.65 |
| Discount or Premium to NAV | -0.04% |
| Turnover Ratio | 18.00 |
View All IBB News
IBB News
-
WireHeadlineTime (ET)
-
SA Breaking News08/22 15:29
-
MT Newswires08/22 13:38
-
MT Newswires08/22 09:24
-
MT Newswires08/21 13:31
-
MT Newswires08/21 09:28
-
MT Newswires08/18 13:26
-
Yahoo08/18 10:20
-
MT Newswires08/18 09:21
-
MT Newswires08/17 13:24
-
MT Newswires08/17 09:23
IBB Performance
| Total Return | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|
| 1M | -6.22% | -4.98% | 88 |
| 3M | 4.96% | 3.16% | 21 |
| 6M | 4.22% | 5.44% | 70 |
| 1Y | 5.18% | 8.28% | 71 |
| 3Y | 4.97% | 7.44% | 77 |
| 5Y | 18.27% | 16.68% | 35 |
| 10Y | 14.86% | 11.41% | 8 |
IBB Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.09% | 0.09% | 0.00 |
| Stock | 99.91% | 99.91% | 0.00 |
| Bond | 0.00 | 0.00 | 0.00 |
| Convertible | 0.00 | 0.00 | 0.00 |
| Preferred | 0.00 | 0.00 | 0.00 |
| Other | 0.00 | 0.00 | 0.00 |
IBB Region Exposure
| Americas | 98.41% |
| North America | 98.41% |
| Latin America | 0.00 |
| Greater Europe | 1.21% |
| United Kingdom | 0.49% |
| Europe Developed | 0.67% |
| Europe Emerging | 0.00 |
| Africa/Middle East | 0.05% |
| Greater Asia | 0.38% |
| Japan | 0.00 |
| Australasia | 0.00 |
| Asia Developed | 0.00 |
| Asia Emerging | 0.38% |
| Market Classification | |
| % Developed Markets | 99.62% |
| % Emerging Markets | 0.38% |
IBB Stock Sector Exposure
| Basic Materials | 0.00 |
| Communication Services | 0.00 |
| Consumer Cyclical | 0.00 |
| Consumer Defensive | 0.00 |
| Energy | 0.00 |
| Financial Services | 0.00 |
| Healthcare | 99.94% |
| Industrials | 0.00 |
| Real Estate | 0.00 |
| Technology | 0.06% |
| Utilities | 0.00 |
IBB Stock Market Capitalization
| Giant | 24.97% |
| Large | 34.93% |
| Medium | 17.38% |
| Small | 14.36% |
| Micro | 8.36% |
IBB Stock Style Exposure
| Large Cap Value | 10.13% |
| Large Cap Blend | 17.49% |
| Large Cap Growth | 33.88% |
| Mid Cap Value | 2.60% |
| Mid Cap Blend | 0.77% |
| Mid Cap Growth | 14.49% |
| Small Cap Value | 1.34% |
| Small Cap Blend | 2.64% |
| Small Cap Growth | 16.66% |
View More Holdings
As of Aug. 21, 2017
IBB Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| BIIB | Biogen Inc | 8.57% | 286.72 | +1.26% |
| GILD | Gilead Sciences Inc | 8.39% | 73.34 | +1.02% |
| CELG | Celgene Corp | 8.35% | 130.29 | +2.24% |
| AMGN | Amgen Inc | 8.12% | 170.07 | +1.14% |
| REGN | Regeneron Pharmaceuticals Inc | 7.36% | 478.65 | +1.90% |
| ALXN | Alexion Pharmaceuticals Inc | 4.63% | 138.20 | +3.57% |
| VRTX | Vertex Pharmaceuticals Inc | 4.52% | 155.48 | +4.34% |
| ILMN | Illumina Inc | 4.03% | 194.76 | +2.14% |
| INCY | Incyte Corp | 3.50% | 123.86 | +2.46% |
| MYL | Mylan NV | 2.52% | 30.73 | +0.95% |
Advertisement
IBB One Page Reports
- One Page Report Download
IBB Basic Info
| Style | |
|---|---|
| Equity Style | Mid Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Benchmark Index | |
|---|---|
NASDAQ Biotechnology TR USD |
100.0% |
IBB Manager Info
| Name | Tenure |
|---|---|
| Alan Mason | 1.29 yrs |
| Diane Hsiung | 9.59 yrs |
| Greg Savage | 9.59 yrs |
| Jennifer Hsui | 5.00 yrs |
IBB Net Fund Flows
| 1M | -210.11M |
| 3M | 825.52M |
| 6M | 477.92M |
| YTD | 457.29M |
| 1Y | 1.424B |
| 3Y | 3.171B |
| 5Y | 4.028B |
| 10Y | 4.309B |
IBB Risk Info
| Beta (5Y) | 1.376 |
| Max Drawdown (All) | 62.85% |
| Historical Sharpe (10Y) | 0.8206 |
| Historical Sortino (All) | 0.5837 |
| 30-Day Rolling Volatility | 15.47% |
| Daily Value at Risk (VaR) 1% (All) | 4.85% |
| Monthly Value at Risk (VaR) 1% (All) | 19.64% |
IBB Fundamentals
| Dividend Yield TTM (8-22-17) | 0.21% |
| SEC Yield (12-31-15) | 0.00% |
| Weighted Average PE Ratio | 22.53 |
| Weighted Average Price to Sales Ratio | 6.397 |
| Weighted Average Price to Book Ratio | 5.329 |
| Weighted Median ROE | 10.23% |
| Weighted Median ROA | -1.69% |
| Forecasted Dividend Yield | 0.57% |
| Forecasted PE Ratio | 21.23 |
| Forecasted Price to Sales Ratio | 5.152 |
| Forecasted Price to Book Ratio | 4.079 |
| Number of Holdings | 163 |
IBB Growth Estimates
| Forecasted 5 Yr Earnings Growth | 10.32% |
| Forecasted Book Value Growth | 16.54% |
| Forecasted Cash Flow Growth | 16.52% |
| Forecasted Earnings Growth | 13.39% |
| Forecasted Revenue Growth | 15.39% |
IBB Comparables
EditIBB Attributes
| Key Dates | |
|---|---|
| Inception Date | 2/5/2001 |
| Last Annual Report Date | 3/31/2017 |
| Last Prospectus Date | 8/1/2017 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
IBB Excel Add-In Codes
- Name: =YCI("IBB","name")
- Broad Asset Class: =YCI("IBB", "broad_asset_class")
- Broad Category: =YCI("IBB", "broad_category_group")
- Prospectus Objective: =YCI("IBB", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
